{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:35:36Z","timestamp":1790400936161,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s10875-012-9656-5","type":"journal-article","created":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T16:09:13Z","timestamp":1330963753000},"page":"663-669","source":"Crossref","is-referenced-by-count":49,"title":["Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency"],"prefix":"10.1007","volume":"32","author":[{"given":"Richard L.","family":"Wasserman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Strausbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ballow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Elkayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lumry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Suez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed M.","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,6]]},"reference":[{"key":"9656_CR1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC. Agammaglobulinema. Pediatrics. 1952;9:722\u20137.","journal-title":"Pediatrics"},{"key":"9656_CR2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","volume":"68","author":"EJ Cohn","year":"1946","unstructured":"Cohn EJ, Strong LE, Hughes Jr WL, et al. Preparation and properties of serum and plasma proteins III: A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459\u201375.","journal-title":"J Am Chem Soc"},{"key":"9656_CR3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1021\/ja01170a048","volume":"71","author":"JL Melin","year":"1949","unstructured":"Melin JL, Oncley M, Richert DA, et al. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta-lipoprotein into subfractions of human plasma. J Am Chem Soc. 1949;71:541\u201350.","journal-title":"J Am Chem Soc"},{"key":"9656_CR4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1537-2995.1986.26286152919.x","volume":"6","author":"MA Wells","year":"1986","unstructured":"Wells MA, Wittek AE, Epstein JS, Marcus-Sekura C, Daniel S, Tankersley DL, et al. Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion. 1986;6:210\u20133.","journal-title":"Transfusion"},{"key":"9656_CR5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1537-2995.1986.26486262753.x","volume":"26","author":"G Mitra","year":"1986","unstructured":"Mitra G, Wong MF, Mozen MM, McDougal JS, Levy JA. Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion. 1986;26:394\u20137.","journal-title":"Transfusion"},{"key":"9656_CR6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1537-2995.1992.32993110753.x","volume":"32","author":"S Yei","year":"1992","unstructured":"Yei S, Yu MW, Tankersley DL. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion. 1992;32:824\u20138.","journal-title":"Transfusion"},{"key":"9656_CR7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1046\/j.1537-2995.1985.25686071422.x","volume":"25","author":"B Horowitz","year":"1985","unstructured":"Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives I: Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations. Transfusion. 1985;25:516\u201322.","journal-title":"Transfusion"},{"key":"9656_CR8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1046\/j.1537-2995.2002.00145.x","volume":"42","author":"A Omar","year":"2002","unstructured":"Omar A, Kempf C. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion. 2002;42:1005\u201310.","journal-title":"Transfusion"},{"key":"9656_CR9","unstructured":"FDA\/CBER. Guidance for industry: Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (Human) as replacement therapy for primary humoral immunodeficiency, http:\/\/www.fda.gov.cber\/gdlns\/igivimmuno.htm , June 2008."},{"issue":"3","key":"9656_CR10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/B:JOCI.0000025453.23817.3f","volume":"24","author":"HD Ochs","year":"2004","unstructured":"Ochs HD, Pinciaro PJ, et al. Octagam\u00ae 5%, an Intravenous IgG Product, is efficacious and well tolerated in patients with primary immunodeficiency diseases. J Clin Immunol. 2004;24(3):309\u201314.","journal-title":"J Clin Immunol"},{"issue":"4","key":"9656_CR11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/B:JOCI.0000029108.18995.61","volume":"24","author":"M Berger","year":"2004","unstructured":"Berger M, Pinciaro PJ, et al. Safety, efficacy and pharmacokinetics of flebogamma\u00ae 5% [Immune Globulin Intravenous (Human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol. 2004;24(4):389\u201396.","journal-title":"J Clin Immunol"},{"key":"9656_CR12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10875-007-9107-x","volume":"27","author":"M Berger","year":"2007","unstructured":"Berger M, et al. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma\u00ae 5% DIF, the next generation of Flebogamma. J Clin Immunol. 2007;27:628\u201333.","journal-title":"J Clin Immunol"},{"key":"9656_CR13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-006-9025-3","volume":"26","author":"JA Church","year":"2006","unstructured":"Church JA, Leibl H, Stein MR, Melamed IR, Rubinstein A, Schneider LC, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin (IGIV 10%) in patients with primary immunodeficiency. J Clin Immunol. 2006;26:388\u201395.","journal-title":"J Clin Immunol"},{"key":"9656_CR14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10875-008-9231-2","volume":"29","author":"MR Stein","year":"2009","unstructured":"Stein MR, Nelson RP, Church JA, Wasserman RL, Church JA, Wasserman RL, et al. Safety and efficacy of Privigen\u00ae, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29:137\u201344.","journal-title":"J Clin Immunol"},{"key":"9656_CR15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10875-009-9348-y","volume":"30","author":"M Berger","year":"2010","unstructured":"Berger M, Pinciaro PJ, Althaus A, Ballow M, Chouksey A, Moy J, et al. Efficacy, pharmacokinetics, safety, and tolerability of flebogamma\u00ae 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010;30:321\u20139.","journal-title":"J Clin Immunol"},{"key":"9656_CR16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-3038.1994.tb00222.x","volume":"5","author":"RI Schiff","year":"1994","unstructured":"Schiff RI. Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action. Pediatr Allergy Immunol. 1994;5:63\u201387.","journal-title":"Pediatr Allergy Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10875-012-9656-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T03:58:03Z","timestamp":1641009483000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-012-9656-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,6]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["9656"],"URL":"https:\/\/doi.org\/10.1007\/s10875-012-9656-5","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,6]]}}}